There has been a roller coaster of events concerning Moderna (MRNA) and its attempt to get approval for its mRNA flu vaccine. Initially, the FDA refused to review the application, leading to a drop in Moderna's stock by 6.4%. Their rationale for the refusal was questioned by Moderna as inconsistent. The agency later reversed its stance and agreed to review the vaccine application, causing a rise in Moderna's stock price.
Separately, Moderna became embroiled in a patent fight, resulting in a settlement costing up to $2.25 billion. Additionally, Moderna sought to bolster their portfolios with promising results with a 2-in-1 flu and COVID-19 vaccine, contributing to a 16% climb in their stocks. The company is also expanding its US manufacturing network, with a $140 million investment in Norwood, MA.
Despite these strides, share prices fell 5.7% after costly settlements and updates for multi-pathogen trials. The rejection of Moderna’s flu vaccine also cast a shadow over Moderna's valuation, despite the encouraging signs in their mRNA technology.
Moderna MRNA News Analytics from Thu, 31 Jul 2025 07:00:00 GMT to Fri, 20 Mar 2026 21:50:03 GMT - Rating 2 - Innovation 7 - Information 7 - Rumor -7
